Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Johnson & Johnson
Johnson & Johnson News
Johnson & Johnson Quantitative Score
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Johnson & Johnson Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Johnson & Johnson Financials
Table Compare
Compare JNJ metrics with: | |||
|---|---|---|---|
Earnings & Growth | JNJ | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | JNJ | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | JNJ | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | JNJ | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Johnson & Johnson Income
Johnson & Johnson Balance Sheet
Johnson & Johnson Cash Flow
Johnson & Johnson Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Johnson & Johnson Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 5.1400 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-12-09 | 1.3 | Quarterly |
| 2025-09-09 | 1.3 | Quarterly |
| 2025-06-10 | 1.3 | Quarterly |
| 2025-03-04 | 1.24 | Quarterly |
| 2024-12-10 | 1.24 | Quarterly |
Historical Market Cap
Shares Outstanding
Johnson & Johnson Executives
| Name | Role |
|---|---|
| Mr. Timothy Schmid | Executive Vice President & Worldwide Chairman of MedTech |
| Mr. Joaquin Duato | Chief Executive Officer & Chairman |
| Ms. Jennifer L. Taubert | Executive Vice President & Worldwide Chairman of Innovative Medicine |
| Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine, R&D |
| Mr. Robert J. Decker Jr. | Controller & Chief Accounting Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Timothy Schmid | Executive Vice President & Worldwide Chairman of MedTech | Male | 1970 | 6.34M |
| Mr. Joaquin Duato | Chief Executive Officer & Chairman | Male | 1963 | 5.9M |
| Ms. Jennifer L. Taubert | Executive Vice President & Worldwide Chairman of Innovative Medicine | Female | 1964 | 3.16M |
| Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine, R&D | 1958 | 3.11M | |
| Mr. Robert J. Decker Jr. | Controller & Chief Accounting Officer | Male | 1973 | -- |
Johnson & Johnson Insider Trades
| Date | 9 Dec |
| Name | Woods Eugene A. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 185.533 |
| Date | 9 Dec |
| Name | HEWSON MARILLYN A |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 247.378 |
| Date | 9 Dec |
| Name | Pinto Daniel E |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 154.611 |
| Date | 26 Nov |
| Name | MORIKIS JOHN G |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 1250 |
| Date | 17 Oct |
| Name | REED JOHN C |
| Role | EVP, Innovative Medicine, R&D |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 21721 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 9 Dec | Woods Eugene A. | Director | Acquired | A-Award | 185.533 |
| 9 Dec | HEWSON MARILLYN A | Director | Acquired | A-Award | 247.378 |
| 9 Dec | Pinto Daniel E | Director | Acquired | A-Award | 154.611 |
| 26 Nov | MORIKIS JOHN G | Director | Acquired | P-Purchase | 1250 |
| 17 Oct | REED JOHN C | EVP, Innovative Medicine, R&D | Acquired | M-Exempt | 21721 |